<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="212">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 08, 2015</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02219074</url>
  </required_header>
  <id_info>
    <org_study_id>SEB-0005</org_study_id>
    <nct_id>NCT02219074</nct_id>
  </id_info>
  <brief_title>Multiple Arm Study of Sebacia Microparticles in the Treatment of Acne Vulgaris</brief_title>
  <official_title>A Feasibility Study to Evaluate the Safety and Preliminary Efficacy of the Sebacia Acne Treatment System for the Treatment of Acne Vulgaris</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sebacia, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sebacia, Inc.</source>
  <oversight_info>
    <authority>Poland: Ministry of Health</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prospective, multicenter study with multiple arms to examine the safety and effectiveness of
      the Sebacia Acne Treatment System for the treatment of acne vulgaris.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2011</start_date>
  <primary_completion_date type="Anticipated">May 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety/Efficacy Study, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Change in inflammatory lesion count</measure>
    <time_frame>Week 12</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of adverse events</measure>
    <time_frame>Screening to 26 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Investigator Global Assessment</measure>
    <time_frame>Week 12</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">310</enrollment>
  <condition>Acne Vulgaris</condition>
  <arm_group>
    <arm_group_label>Sebacia microparticle and laser treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Sebacia microparticle and laser treatment</intervention_name>
    <arm_group_label>Sebacia microparticle and laser treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  clinical diagnosis of moderate to severe acne vulgaris

        Exclusion Criteria:

          -  use of oral retinoid therapy in the past 12 months

          -  pregnancy, lactating, or planning to become pregnant

          -  excessive scarring in the treatment area, or other condition that would impact the
               ability to evaluate acne
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Dariusz Joseph, PhD</last_name>
    <phone>+48 22 378 6000</phone>
    <email>Dariusz.Joseph@noblewell.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Specjalistyczny Gabinet Dermatologiczny</name>
      <address>
        <city>Krakow</city>
        <zip>31-530</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Military Institute of Health Services</name>
      <address>
        <city>Warsaw</city>
        <zip>04-141</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Poland</country>
  </location_countries>
  <verification_date>September 2014</verification_date>
  <lastchanged_date>September 16, 2014</lastchanged_date>
  <firstreceived_date>August 14, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Acne Vulgaris</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
